Tom Price Was Not 100% Truthful About His Forays In the Penny Stock Market

Let our journalists help you make sense of the noise: Subscribe to the Mother Jones Daily newsletter and get a recap of news that matters.

Rep. Tom Price has been dogged for weeks by allegations that he got a special deal on stock in Innate Immunotherapeutics Ltd. thanks to his status as a senior member of the House leadership (he’s chairman of the Budget Committee). Price says it’s all hooey: the deal he got was available to anyone who had invested in the company.

But now that turns out to be—what’s the word? A falsehood. You know, the deliberate kind. Here’s the Wall Street Journal:

In fact, the cabinet nominee was one of fewer than 20 U.S. investors who were invited last year to buy discounted shares of the company—an opportunity that, for Mr. Price, arose from an invitation from a company director and fellow congressmen.

The shares were discounted 12% off the traded price in mid-June only for investors who participated in a private placement arranged to raise money to complete a clinical trial. The company’s shares have tripled since the offering.

….The discounted stock offer in Innate Immuno, as the company is known, was made to all shareholders in Australia and New Zealand—but not in the U.S….[Price] said he paid the same price as other investors in the private placement but didn’t say that the 12% discount wasn’t available to ordinary investors or that he was one of a select few who were invited to participate in the deal.

This was a “friends and family” deal, which is not uncommon for small companies doing private placements. The question is, why did Price lie about it? It’s not illegal, and I don’t think it violates congressional ethics rules. So what’s going on here? Price doesn’t even work for Donald Trump yet, but apparently he’s already adopted the Trumpian habit of lying about everything even if you don’t need to. It’s good practice, I guess.

Anyway, as you can see the stock was a helluva deal for Price, rising from 29 cents (25 cents with the discount!) to $1.77 over the course of seven months. Sadly, on Friday and Monday there was a sudden selloff, and now the stock is down to 78 cents. Apparently the recent press attention has spooked a few investors. Still not a bad return for a few months’ work, though.


Headshot of Editor in Chief of Mother Jones, Clara Jeffery

It sure feels that way to me, and here at Mother Jones, we’ve been thinking a lot about what journalism needs to do differently, and how we can have the biggest impact.

We kept coming back to one word: corruption. Democracy and the rule of law being undermined by those with wealth and power for their own gain. So we're launching an ambitious Mother Jones Corruption Project to do deep, time-intensive reporting on systemic corruption, and asking the MoJo community to help crowdfund it.

We aim to hire, build a team, and give them the time and space needed to understand how we got here and how we might get out. We want to dig into the forces and decisions that have allowed massive conflicts of interest, influence peddling, and win-at-all-costs politics to flourish.

It's unlike anything we've done, and we have seed funding to get started, but we're looking to raise $500,000 from readers by July when we'll be making key budgeting decisions—and the more resources we have by then, the deeper we can dig. If our plan sounds good to you, please help kickstart it with a tax-deductible donation today.

Thanks for reading—whether or not you can pitch in today, or ever, I'm glad you're with us.

Signed by Clara Jeffery

Clara Jeffery, Editor-in-Chief

payment methods

We Recommend